Abstract
Detection technologies of minimal residual disease(MRD) have emerged with the development of multiple myeloma (MM) therapies. It can not only reflect the depth of disease response, but also predict the prognosis, indicate recurrence of myeloma patients, and can be used as an important reference for clinical treatment decisions. Long-term sustained MRD negativity has become a globally recognized goal for MM treatment, but there are still many problems to be solved in daily clinical practice. In addition, it is necessary to clarify its biological characteristics through basic research so that it can be better applied in clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
